Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimodipine oral solution vs injection/tablets in postoperative aneurysmal subarachnoid hemorrhage
ChiCTR2400080922Phase 4Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nimodipine in subarachnoid hemorrhage (SAH) (3 arms), sponsored by Xuanwu Hospital. Primary endpoint: Favorable functional outcome at day 90. Started Feb 2024; status: recruiting.
02
Drugs
nimodipine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ChiCTR2400080922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080922.